Aptazapine

Aptazapine (developmental code name CGS-7525A) is a tetracyclic antidepressant (TeCA) that was assayed in clinical trials for the treatment of depression in the 1980s but was never marketed.^[1][2][3] It is a potent α₂-adrenergic receptor antagonist with about 10 times the strength of the related compound mianserin and has also been shown to act as a 5-HT₂ receptor antagonist and H₁ receptor inverse agonist, while having no significant effects on the reuptake of serotonin or norepinephrine.^[1][4] Based on its pharmacological profile, aptazapine may be classified as a noradrenergic and specific serotonergic antidepressant (NaSSA).

Aptazapine

Clinical data
ATC code	none
Identifiers
IUPAC name 2-methyl-1,3,4,14b-tetrahydro-2H,10H-pyrazino[1,2-a]pyrrolo[2,1-c][1,4]benzodiazepine
CAS Number	71576-40-4 N
PubChem CID	51355
ChemSpider	46513 Y
UNII	240J927J1R
KEGG	D02972 Y
ChEMBL	ChEMBL336712 Y
CompTox Dashboard (EPA)	DTXSID40868020
Chemical and physical data
Formula	C16H19N3
Molar mass	253.349 g·mol−1
3D model (JSmol)	Interactive image
SMILES c42c(N3C(c1cccn1C2)CN(CC3)C)cccc4
InChI InChI=1S/C16H19N3/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17/h2-8,16H,9-12H2,1H3 Y Key:MNHDDERDSNZCCK-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

See also

• Mianserin
• Mirtazapine
• Setiptiline